The World Health Organization said Tuesday it is in discussions with Pfizer and Moderna about possibly including their high-tech coronavirus vaccines among early jabs for poor countries at affordable prices.
The WHO-backed Covax facility, created to ensure equitable access to Covid-19 vaccines around the world as they become available, is aiming to provide some two billion doses by the end of next year.
It has already secured hundreds of millions of doses of vaccine candidates being developed by AstraZeneca, Novavax, and Sanofi-GSK.
WHO senior advisor Bruce Aylward said the organization was looking at a range of other jabs, as well as the current frontrunners.
He said WHO was “in conversations” with Pfizer and Moderna about whether their products could be part of “early roll-out of vaccines”.
But, he stressed, “we also need to make sure that they are at prices that are appropriate for the populations we are trying to serve and the countries we are trying to help.”
US pharmaceutical giant Pfizer has, along with German BioNTech, created the first coronavirus jab to receive regulatory approval in a number of Western countries. Vaccination campaigns have already begun in Britain and the United States.
The Moderna vaccine is expected to quickly receive approvals as well.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.